Company Overview and News

 
SeaDrill's Shares Ride High on Confirmed Restructuring Plans

5h zacks
SeaDrill Limited’s (SDRL - Free Report) shares have increased 64.68% to eventually close at 36.56 cents on Apr 18, reflecting investors’ optimism on the stock after the company’s restructuring plan won approval from the U.S. Bankruptcy Court. Looking Back Hit by the industry downturn, SeaDrill had been going through a rough patch over the last two years, with its shares plummeting more than 91% during the time frame, owing to increased debts and bankruptcy fears.
Upvote Downvote

 
Seadrill To Emerge From Bankruptcy Within Months At A Fraction Of Its Current Valuation

5h seekingalpha
Equity is trading more than 100% above the high end of the valuation range calculated by the company's bankruptcy advisors and 70% above market leader Transocean.
Upvote Downvote

 
Seadrill Gets US Court Approval For Bankruptcy Exit Plan

2018-04-17 rigzone
WILMINGTON, Del., April 17 (Reuters) - A U.S. judge said on Tuesday he would approve Seadrill Ltd's plan to exit its Chapter 11 bankruptcy, in which the global offshore oil and gas drilling company would shed billions of dollars of debt and raise $1 billion in new investment.
Upvote Downvote

 
Ocean Rig: Potential Opportunity Under $24

2018-04-17 seekingalpha
On April 16, 2018, Ocean Rig UDW's BoD announced it had authorized a stock repurchase plan, under which the Company may repurchase up to $150 million of its outstanding shares.
Upvote Downvote

 
ORIG / Ocean Rig UDW Inc. null (Current Report of Foreign Issuer)

2018-04-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BRIEF-Ocean Rig Udw Inc. Announces Authorization Of An Up To $150 Million Stock Repurchase Plan

2018-04-16 reuters
* OCEAN RIG UDW INC. ANNOUNCES AUTHORIZATION OF AN UP TO $150 MILLION STOCK REPURCHASE PLAN
Upvote Downvote

 
Ocean Rig UDW Inc. Announces Authorization of an Up to $150 Million Stock Repurchase Plan

2018-04-16 globenewswire
GRAND CAYMAN, Cayman Islands, April 16, 2018 (GLOBE NEWSWIRE) -- Ocean Rig UDW Inc. (NASDAQ:ORIG) (“Ocean Rig” or the “Company”), a global provider of offshore deepwater drilling services, announced today that its Board of Directors (the “Board”) has authorized a stock repurchase plan (the “Plan”), under which the Company may repurchase up to $150 million of its outstanding common shares for a period of 12 months from a date to be determined by the Board.
Upvote Downvote

 
SeaDrill (SDRL) Wins Solid Support for Restructuring Plans

2018-04-10 zacks
SeaDrill Limited’s (SDRL - Free Report) shares increased 15.12% to eventually close at 23.6 cents on Apr 9, reflecting investors’ optimism after the company received virtually unanimous backing for its reorganization plan. The company’s financial restructuring plan received approval from 99.8% of the creditors. Per the restructuring agreement, the international offshore drilling company will witness capital injection of $1.
Upvote Downvote

 
ORIG / Ocean Rig UDW Inc. null (Current Report of Foreign Issuer)

2018-03-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BRIEF-Ocean Rig UDW Announces $100 Mln Prepayment Of $450 Mln Senior Secured Credit Facility

2018-03-21 reuters
* OCEAN RIG UDW INC. ANNOUNCES $100 MILLION PREPAYMENT OF $450 MILLION SENIOR SECURED CREDIT FACILITY
Upvote Downvote

 
Ocean Rig UDW Inc. Announces $100 Million Prepayment of $450 Million Senior Secured Credit Facility

2018-03-21 globenewswire
GRAND CAYMAN, Cayman Islands , March 21, 2018 (GLOBE NEWSWIRE) -- Ocean Rig UDW Inc. (NASDAQ:ORIG) (“Ocean Rig” or the “Company”), a global provider of offshore deepwater drilling services, announced today that it has prepaid $100 million of its $450 million Senior Secured Term Loan Facility (the “Term Loan”), which bears interest at 8.00% per annum and matures on September 20, 2024. Following the prepayment, the total outstanding borrowings under the Term Loan has been reduced to $350 million.
Upvote Downvote

 
ORIG / Ocean Rig UDW Inc. null

2018-03-19 sec.gov
As filed with the Securities and Exchange Commission on March 19, 2018. Registration Statement No. 333-_____________________
Upvote Downvote

 
ORIG / Ocean Rig UDW Inc. null (Current Report of Foreign Issuer)

2018-03-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
Ocean Rig UDW Inc. Announces Availability of 2017 Annual Report on Form 20-F

2018-03-15 globenewswire
GRAND CAYMAN, Cayman Islands, March 15, 2018 (GLOBE NEWSWIRE) -- Ocean Rig UDW Inc. (NASDAQ:ORIG) (“Ocean Rig”), a global provider of offshore deepwater drilling services, announced today that its annual report on Form 20-F for the year ended December 31, 2017 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission. The Annual Report may also be accessed through the Ocean Rig website, www.
Upvote Downvote

 
ORIG / Ocean Rig UDW Inc. null

2018-03-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTO
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: Y64354205